Learn in-demand skills with online courses and Professional Certificates from leading companies like Google, IBM, Meta, and Adobe. Explore flexible programs—from short courses to full degrees.

Reprogramming the immune system. Restoring lives. At COUR, we develop targeted therapies that incite calm within the immune system and help restore the health of people suffering from …

Find the latest Coursera, Inc. (COUR) stock quote, history, news and other vital information to help you with your stock trading and investing.

Dec 3, 2024 · Roche’s Genentech unit has tapped Cour to help develop and commercialize the biotech’s bespoke tolerogenic nanoparticle treatments for autoimmune diseases, Cour said Tuesday.

Get real-time Coursera Inc (COUR) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

Jan 30, 2024 · Biotechnology startup Cour Pharmaceuticals has raised $105 million to advance a portfolio of medicines for autoimmune diseases. The startup’s funding was co-led by Alpha Wave …

Feb 18, 2025 · COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart was approved for the disease in 2021 while Johnson & Johnson has filed for approval of nipocalimab and …

With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.

Nov 21, 2024 · COUR Pharmaceuticals is relocating its headquarters from Skokie to a Trammell Crow Company development in Evanston.

4 days ago · When is Coursera's next earnings announcement? View the latest COUR earnings date, analysts forecasts, earnings history, and conference call transcripts.